Brokerages Set Recro Pharma Inc (REPH) Price Target at $13.20


Shares of Recro Pharma Inc (NASDAQ:REPH) have earned an average rating of “Buy” from the ten analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $13.20.

REPH has been the topic of a number of research reports. Oppenheimer set a $19.00 target price on shares of Recro Pharma and gave the stock a “buy” rating in a report on Wednesday, February 28th. ValuEngine raised shares of Recro Pharma from a “sell” rating to a “hold” rating in a report on Thursday, March 1st. Zacks Investment Research raised shares of Recro Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, March 21st. Berenberg Bank started coverage on shares of Recro Pharma in a report on Thursday, April 19th. They set a “buy” rating on the stock. Finally, BidaskClub raised shares of Recro Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, May 24th.


Get Recro Pharma alerts:

REPH traded up $0.19 during trading on Monday, reaching $5.25. 1,198,017 shares of the company’s stock were exchanged, compared to its average volume of 374,623. Recro Pharma has a one year low of $4.96 and a one year high of $13.05. The company has a debt-to-equity ratio of 2.20, a current ratio of 1.78 and a quick ratio of 1.55. The firm has a market capitalization of $103.77 million, a price-to-earnings ratio of -2.64 and a beta of -0.97.

Recro Pharma (NASDAQ:REPH) last posted its earnings results on Wednesday, May 9th. The specialty pharmaceutical company reported ($0.65) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.03. Recro Pharma had a negative net margin of 74.85% and a negative return on equity of 105.78%. The firm had revenue of $19.54 million for the quarter, compared to analyst estimates of $17.32 million. equities research analysts predict that Recro Pharma will post -3.1 EPS for the current year.


In other news, major shareholder Healthcare Master Fun Broadfin sold 188,000 shares of the company’s stock in a transaction on Thursday, May 24th. The shares were sold at an average price of $5.81, for a total value of $1,092,280.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 21.60% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Lyon Street Capital LLC boosted its stake in shares of Recro Pharma by 182.6% in the 1st quarter. Lyon Street Capital LLC now owns 1,027,271 shares of the specialty pharmaceutical company’s stock valued at $11,310,000 after purchasing an additional 663,776 shares during the last quarter. BlackRock Inc. boosted its stake in Recro Pharma by 1.4% during the fourth quarter. BlackRock Inc. now owns 1,011,855 shares of the specialty pharmaceutical company’s stock worth $9,359,000 after acquiring an additional 13,799 shares in the last quarter. Sphera Funds Management LTD. bought a new position in Recro Pharma during the first quarter worth $4,010,000. Millennium Management LLC bought a new position in Recro Pharma during the first quarter worth $3,060,000. Finally, The Manufacturers Life Insurance Company boosted its stake in Recro Pharma by 6,480.5% during the first quarter. The Manufacturers Life Insurance Company now owns 235,712 shares of the specialty pharmaceutical company’s stock worth $2,595,000 after acquiring an additional 232,130 shares in the last quarter. 56.15% of the stock is currently owned by institutional investors.


Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Leave a Reply

Your email address will not be published.